Written questions by Vickers.

What steps his Department is taking to ensure the adequacy of the workforce capacity in community settings to help reduce pressure on elective backlogs.

The 10-Year Health Plan committed to shifting care from the hospital to the community and to introducing Neighbourhood Health Services to bring together teams of professionals closer to people’s homes to work together to provide comprehensive care in the community. We will publish a 10 Year Workforce Plan to create a workforce ready to deliver these transformed services. The plan will ensure that the National Health Service has the right people in the right places, with the right skills to care for patients, when they need it.

Whether his Department has set targets for reducing waiting lists by aligning them with (a) workforce growth and (b) deployment metrics.

As set out in the Plan for Change, we will ensure that 92% of patients return to waiting no longer than 18 weeks from referral to treatment by March 2029, a standard which has not been met consistently since September 2015. NHS England published its planning guidance for 2025/26 in January 2025. This guidance sets out clear priorities for the National Health Service, including the delivery of the interim electives ambition that nationally, 65% of patients are seen within 18 weeks, along with an expected minimum 5% improvement on current performance for each trust, as set out in the Elective Reform Plan. It is for trusts and integrated care boards to manage the staffing of all professions to deliver on these priorities within their agreed financial allocations.We will publish a 10 Year Workforce Plan to create a workforce ready to deliver a transformed service. They will be more empowered, more flexible, and more fulfilled. The 10 Year Workforce Plan will ensure the NHS has the right people in the right places, with the right skills to care for patients, when they need it.

What assessment his Department has made of the potential impact of staffing shortages in non-clinical roles on waiting lists.

The Department has not made an assessment of the potential impact of staffing shortages in non-clinical roles, workforce burnout, reductions in the number of interim board positions, or regional retention offers on waiting lists, or of creating temporary cross-trust staffing pools for specialties with high waiting times. No assessment has been made of the potential impact of regional retention offers on reducing workforce turnover.The Government is committed to making the National Health Service the best place to work, by supporting and retaining our hardworking and dedicated healthcare professionals. The Government plans to introduce a new set of standards for modern employment in April 2026. The new standards will reaffirm our commitment to improving retention by tackling the issues that matter to staff, including promoting flexible working, improving staff health and wellbeing, and dealing with violence, racism, and sexual harassment in the NHS workplace.The health and wellbeing of all NHS staff is a top priority. NHS organisations have a responsibility to create supportive working environments for staff, ensuring they have the conditions they need to thrive, including access to high quality health and wellbeing support. As set out in the 10-Year Health Plan, we will roll out Staff Treatment hubs to ensure all staff have access to high quality occupational health support, including for mental health.NHS England published its planning guidance for 2025/26 in January 2025. This guidance sets out clear priorities for the NHS, including the delivery of the interim electives ambition that nationally, 65% of patients are seen within 18 weeks, along with an expected minimum 5% improvement on current performance for each trust, as set out in the Elective Reform Plan. Trusts and integrated care boards are expected to manage the staffing of all professions to deliver on these priorities within their agreed financial allocations.

Whether he has made an assessment of the potential impact of regional retention offers on reducing (a) workforce turnover and (b) waiting list lengths.

The Department has not made an assessment of the potential impact of staffing shortages in non-clinical roles, workforce burnout, reductions in the number of interim board positions, or regional retention offers on waiting lists, or of creating temporary cross-trust staffing pools for specialties with high waiting times. No assessment has been made of the potential impact of regional retention offers on reducing workforce turnover.The Government is committed to making the National Health Service the best place to work, by supporting and retaining our hardworking and dedicated healthcare professionals. The Government plans to introduce a new set of standards for modern employment in April 2026. The new standards will reaffirm our commitment to improving retention by tackling the issues that matter to staff, including promoting flexible working, improving staff health and wellbeing, and dealing with violence, racism, and sexual harassment in the NHS workplace.The health and wellbeing of all NHS staff is a top priority. NHS organisations have a responsibility to create supportive working environments for staff, ensuring they have the conditions they need to thrive, including access to high quality health and wellbeing support. As set out in the 10-Year Health Plan, we will roll out Staff Treatment hubs to ensure all staff have access to high quality occupational health support, including for mental health.NHS England published its planning guidance for 2025/26 in January 2025. This guidance sets out clear priorities for the NHS, including the delivery of the interim electives ambition that nationally, 65% of patients are seen within 18 weeks, along with an expected minimum 5% improvement on current performance for each trust, as set out in the Elective Reform Plan. Trusts and integrated care boards are expected to manage the staffing of all professions to deliver on these priorities within their agreed financial allocations.

How many and what proportion of Trusts have designated recruitment teams focused on elective care specialties; and whether he plans on rolling out this initiative to more Trusts.

The Department does not hold information on how many and what proportion of trusts have designated recruitment teams focused on elective care specialties.Decisions about recruitment are a matter for individual National Health Service employers, who manage this at a local level to ensure they have the staff they need to deliver safe and effective care.The 10 Year Workforce Plan will ensure the NHS has the right people in the right places, with the right skills to deliver the best care for patients, when they need it.

What steps his Department is taking to consider patient feedback when developing the national cancer plan for blood cancers.

Reducing the number of lives lost to cancer is a key aim of the National Cancer Plan, which will be published later this year. The plan will include further details on how we will improve outcomes for cancer patients, including blood cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, ultimately driving up this country’s cancer survival rates. The National Cancer Plan will have patients at its heart, and the Department has been working closely with patient organisations and other cancer partners as part of our engagement to inform the development of the plan. This includes patient and family engagement events with partners such as Macmillan and Maggies, and engagement with blood cancer charities and the NHS Patient and Public Voice Forum.Early diagnosis is a key focus of the National Cancer Plan. It is a priority for the Government to support the National Health Service to diagnose cancer, including blood cancers, as early and quickly as possible, and to treat it faster, to improve outcomes. To tackle the late diagnoses of blood cancers, the NHS is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways. We will get the NHS diagnosing blood cancers earlier and treating them faster, and we will support the NHS to increase capacity to meet the demand for diagnostic services through investment, including for magnetic resonance imaging and computed tomography scanners. Furthermore, the 10-Year Health Plan’s commitment to putting digital health at the heart of the future health service, and integrating that with a single patient record and neighbourhood health services, will mean that cancer patients will get the joined-up care they deserve.The National Cancer Plan will also seek to ensure that high-quality care is available to patients across the country, including patients in rural areas. This will build on the current national cancer audits, which are seeking to promote best practice and aim to reduce inequalities in the access to, or the quality of, treatment. Further details on the steps that will be taken to achieve this will be set out in the plan. Service providers are responsible for making clinical decisions about prioritisation in response to capacity constraints, taking into consideration national guidance, and access and waiting time standards, so that patients are prioritised.Haematopoietic stem cell transplantation (HSCT) is a potential treatment for a range of malignant and non-malignant indications, including myeloma. HSCT is a specialised service and is the commissioning responsibility of integrated care boards.NHS England is the accountable commissioner for HSCT and has published a national service specification that all commissioned HSCT services need to meet. The list of commissioned indications is covered by the NHS England Clinical Commissioning Policy available at the following link:https://www.england.nhs.uk/wp-content/uploads/2022/10/Haematopoietic-Stem-Cell-Transplantation-HSCT-All-Ages.pdfThere are currently no plans to expand the number of specialised centres that deliver HSCT treatments.Blood cancer in and of itself is not a disease that is specialised, however, some of the treatments used to manage blood cancers are within specialised services, such as HSCT. NHS England publishes national service specifications for specialised services and monitors the quality-of-service provision and patient outcomes via the NHS England quality dashboards, and in the case of HSCT, by also reviewing the service-level reports published by the British Society of Blood and Marrow Transplantation and Cellular Therapy. The findings of the reviews of these reports are discussed with NHS England regional teams who determine any appropriate action that needs to be taken with the providers within their region.

If he will take steps to issue guidance to NHS trusts on prioritising blood cancer patients for treatment when demand exceeds capacity.

Reducing the number of lives lost to cancer is a key aim of the National Cancer Plan, which will be published later this year. The plan will include further details on how we will improve outcomes for cancer patients, including blood cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, ultimately driving up this country’s cancer survival rates. The National Cancer Plan will have patients at its heart, and the Department has been working closely with patient organisations and other cancer partners as part of our engagement to inform the development of the plan. This includes patient and family engagement events with partners such as Macmillan and Maggies, and engagement with blood cancer charities and the NHS Patient and Public Voice Forum.Early diagnosis is a key focus of the National Cancer Plan. It is a priority for the Government to support the National Health Service to diagnose cancer, including blood cancers, as early and quickly as possible, and to treat it faster, to improve outcomes. To tackle the late diagnoses of blood cancers, the NHS is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways. We will get the NHS diagnosing blood cancers earlier and treating them faster, and we will support the NHS to increase capacity to meet the demand for diagnostic services through investment, including for magnetic resonance imaging and computed tomography scanners. Furthermore, the 10-Year Health Plan’s commitment to putting digital health at the heart of the future health service, and integrating that with a single patient record and neighbourhood health services, will mean that cancer patients will get the joined-up care they deserve.The National Cancer Plan will also seek to ensure that high-quality care is available to patients across the country, including patients in rural areas. This will build on the current national cancer audits, which are seeking to promote best practice and aim to reduce inequalities in the access to, or the quality of, treatment. Further details on the steps that will be taken to achieve this will be set out in the plan. Service providers are responsible for making clinical decisions about prioritisation in response to capacity constraints, taking into consideration national guidance, and access and waiting time standards, so that patients are prioritised.Haematopoietic stem cell transplantation (HSCT) is a potential treatment for a range of malignant and non-malignant indications, including myeloma. HSCT is a specialised service and is the commissioning responsibility of integrated care boards.NHS England is the accountable commissioner for HSCT and has published a national service specification that all commissioned HSCT services need to meet. The list of commissioned indications is covered by the NHS England Clinical Commissioning Policy available at the following link:https://www.england.nhs.uk/wp-content/uploads/2022/10/Haematopoietic-Stem-Cell-Transplantation-HSCT-All-Ages.pdfThere are currently no plans to expand the number of specialised centres that deliver HSCT treatments.Blood cancer in and of itself is not a disease that is specialised, however, some of the treatments used to manage blood cancers are within specialised services, such as HSCT. NHS England publishes national service specifications for specialised services and monitors the quality-of-service provision and patient outcomes via the NHS England quality dashboards, and in the case of HSCT, by also reviewing the service-level reports published by the British Society of Blood and Marrow Transplantation and Cellular Therapy. The findings of the reviews of these reports are discussed with NHS England regional teams who determine any appropriate action that needs to be taken with the providers within their region.

What progress he has made on rolling out Fracture Liaison Services in all NHS Trusts in England.

Fracture Liaison Services are commissioned by integrated care boards, which are well-placed to make decisions according to local need.Our 10-Year Health Plan committed to rolling out Fracture Liaison Services across every part of the country by 2030.Officials continue to work closely with NHS England to explore a range of options to provide better quality and access to these important preventative services.

What steps his Department is taking to assess the potential impact of centralised specialist services on patient outcomes for different blood cancers.

Reducing the number of lives lost to cancer is a key aim of the National Cancer Plan, which will be published later this year. The plan will include further details on how we will improve outcomes for cancer patients, including blood cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, ultimately driving up this country’s cancer survival rates. The National Cancer Plan will have patients at its heart, and the Department has been working closely with patient organisations and other cancer partners as part of our engagement to inform the development of the plan. This includes patient and family engagement events with partners such as Macmillan and Maggies, and engagement with blood cancer charities and the NHS Patient and Public Voice Forum.Early diagnosis is a key focus of the National Cancer Plan. It is a priority for the Government to support the National Health Service to diagnose cancer, including blood cancers, as early and quickly as possible, and to treat it faster, to improve outcomes. To tackle the late diagnoses of blood cancers, the NHS is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways. We will get the NHS diagnosing blood cancers earlier and treating them faster, and we will support the NHS to increase capacity to meet the demand for diagnostic services through investment, including for magnetic resonance imaging and computed tomography scanners. Furthermore, the 10-Year Health Plan’s commitment to putting digital health at the heart of the future health service, and integrating that with a single patient record and neighbourhood health services, will mean that cancer patients will get the joined-up care they deserve.The National Cancer Plan will also seek to ensure that high-quality care is available to patients across the country, including patients in rural areas. This will build on the current national cancer audits, which are seeking to promote best practice and aim to reduce inequalities in the access to, or the quality of, treatment. Further details on the steps that will be taken to achieve this will be set out in the plan. Service providers are responsible for making clinical decisions about prioritisation in response to capacity constraints, taking into consideration national guidance, and access and waiting time standards, so that patients are prioritised.Haematopoietic stem cell transplantation (HSCT) is a potential treatment for a range of malignant and non-malignant indications, including myeloma. HSCT is a specialised service and is the commissioning responsibility of integrated care boards.NHS England is the accountable commissioner for HSCT and has published a national service specification that all commissioned HSCT services need to meet. The list of commissioned indications is covered by the NHS England Clinical Commissioning Policy available at the following link:https://www.england.nhs.uk/wp-content/uploads/2022/10/Haematopoietic-Stem-Cell-Transplantation-HSCT-All-Ages.pdfThere are currently no plans to expand the number of specialised centres that deliver HSCT treatments.Blood cancer in and of itself is not a disease that is specialised, however, some of the treatments used to manage blood cancers are within specialised services, such as HSCT. NHS England publishes national service specifications for specialised services and monitors the quality-of-service provision and patient outcomes via the NHS England quality dashboards, and in the case of HSCT, by also reviewing the service-level reports published by the British Society of Blood and Marrow Transplantation and Cellular Therapy. The findings of the reviews of these reports are discussed with NHS England regional teams who determine any appropriate action that needs to be taken with the providers within their region.

What steps he is taking to ensure that people presenting with fragility fractures are systematically referred for a bone density scan.

Fracture Liaison Services are commissioned by integrated care boards, which are well-placed to make decisions according to local need.Our 10-Year Health Plan committed to rolling out Fracture Liaison Services across every part of the country by 2030.Officials continue to work closely with NHS England to explore a range of options to provide better quality and access to these important preventative services.

What assessment he has made of the potential implications for his policies of international best practice in the provision of osteoporosis diagnosis services; and whether he is applying lessons learned from those practices to NHS policy.

In the last three years, two new drugs have been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of osteoporosis in post-menopausal women, namely abaloparatide and romosozumab. These medications help to strengthen the bones and prevent bone loss, thereby reducing the risk of fractures. The National Health Service is legally required to make funding available for treatments recommended by NICE.We have invested in 13 new bone density, or DEXA, scanners, which are expected to provide up to 29,000 extra scans per year to ensure people with bone conditions get diagnosed earlier.The National Fracture Liaison Service database is a clinically led national audit of secondary fracture prevention in England and Wales and is commissioned by the Healthcare Quality Improvement Partnership and delivered by the Royal College of Physicians. It collects and publishes data on individual Fracture Liaison Services and uses internationally recognised standards as the key performance indicators that these services are measured against. The data is publicly available.

Whether his Department plans to expand the number of specialist centres for myeloma treatment.

Reducing the number of lives lost to cancer is a key aim of the National Cancer Plan, which will be published later this year. The plan will include further details on how we will improve outcomes for cancer patients, including blood cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, ultimately driving up this country’s cancer survival rates. The National Cancer Plan will have patients at its heart, and the Department has been working closely with patient organisations and other cancer partners as part of our engagement to inform the development of the plan. This includes patient and family engagement events with partners such as Macmillan and Maggies, and engagement with blood cancer charities and the NHS Patient and Public Voice Forum.Early diagnosis is a key focus of the National Cancer Plan. It is a priority for the Government to support the National Health Service to diagnose cancer, including blood cancers, as early and quickly as possible, and to treat it faster, to improve outcomes. To tackle the late diagnoses of blood cancers, the NHS is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways. We will get the NHS diagnosing blood cancers earlier and treating them faster, and we will support the NHS to increase capacity to meet the demand for diagnostic services through investment, including for magnetic resonance imaging and computed tomography scanners. Furthermore, the 10-Year Health Plan’s commitment to putting digital health at the heart of the future health service, and integrating that with a single patient record and neighbourhood health services, will mean that cancer patients will get the joined-up care they deserve.The National Cancer Plan will also seek to ensure that high-quality care is available to patients across the country, including patients in rural areas. This will build on the current national cancer audits, which are seeking to promote best practice and aim to reduce inequalities in the access to, or the quality of, treatment. Further details on the steps that will be taken to achieve this will be set out in the plan. Service providers are responsible for making clinical decisions about prioritisation in response to capacity constraints, taking into consideration national guidance, and access and waiting time standards, so that patients are prioritised.Haematopoietic stem cell transplantation (HSCT) is a potential treatment for a range of malignant and non-malignant indications, including myeloma. HSCT is a specialised service and is the commissioning responsibility of integrated care boards.NHS England is the accountable commissioner for HSCT and has published a national service specification that all commissioned HSCT services need to meet. The list of commissioned indications is covered by the NHS England Clinical Commissioning Policy available at the following link:https://www.england.nhs.uk/wp-content/uploads/2022/10/Haematopoietic-Stem-Cell-Transplantation-HSCT-All-Ages.pdfThere are currently no plans to expand the number of specialised centres that deliver HSCT treatments.Blood cancer in and of itself is not a disease that is specialised, however, some of the treatments used to manage blood cancers are within specialised services, such as HSCT. NHS England publishes national service specifications for specialised services and monitors the quality-of-service provision and patient outcomes via the NHS England quality dashboards, and in the case of HSCT, by also reviewing the service-level reports published by the British Society of Blood and Marrow Transplantation and Cellular Therapy. The findings of the reviews of these reports are discussed with NHS England regional teams who determine any appropriate action that needs to be taken with the providers within their region.

What recent estimate his Department has made of the cost savings to the NHS from the expansion of Fracture Liaison Services in England.

Potential cost savings to the National Health Service from the expansion of Fracture Liaison Services will be taken into consideration in future policy development.

What assessment he has made of the effectiveness of data sharing between hospitals and primary care in improving early diagnosis of blood cancers.

Reducing the number of lives lost to cancer is a key aim of the National Cancer Plan, which will be published later this year. The plan will include further details on how we will improve outcomes for cancer patients, including blood cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, ultimately driving up this country’s cancer survival rates. The National Cancer Plan will have patients at its heart, and the Department has been working closely with patient organisations and other cancer partners as part of our engagement to inform the development of the plan. This includes patient and family engagement events with partners such as Macmillan and Maggies, and engagement with blood cancer charities and the NHS Patient and Public Voice Forum.Early diagnosis is a key focus of the National Cancer Plan. It is a priority for the Government to support the National Health Service to diagnose cancer, including blood cancers, as early and quickly as possible, and to treat it faster, to improve outcomes. To tackle the late diagnoses of blood cancers, the NHS is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways. We will get the NHS diagnosing blood cancers earlier and treating them faster, and we will support the NHS to increase capacity to meet the demand for diagnostic services through investment, including for magnetic resonance imaging and computed tomography scanners. Furthermore, the 10-Year Health Plan’s commitment to putting digital health at the heart of the future health service, and integrating that with a single patient record and neighbourhood health services, will mean that cancer patients will get the joined-up care they deserve.The National Cancer Plan will also seek to ensure that high-quality care is available to patients across the country, including patients in rural areas. This will build on the current national cancer audits, which are seeking to promote best practice and aim to reduce inequalities in the access to, or the quality of, treatment. Further details on the steps that will be taken to achieve this will be set out in the plan. Service providers are responsible for making clinical decisions about prioritisation in response to capacity constraints, taking into consideration national guidance, and access and waiting time standards, so that patients are prioritised.Haematopoietic stem cell transplantation (HSCT) is a potential treatment for a range of malignant and non-malignant indications, including myeloma. HSCT is a specialised service and is the commissioning responsibility of integrated care boards.NHS England is the accountable commissioner for HSCT and has published a national service specification that all commissioned HSCT services need to meet. The list of commissioned indications is covered by the NHS England Clinical Commissioning Policy available at the following link:https://www.england.nhs.uk/wp-content/uploads/2022/10/Haematopoietic-Stem-Cell-Transplantation-HSCT-All-Ages.pdfThere are currently no plans to expand the number of specialised centres that deliver HSCT treatments.Blood cancer in and of itself is not a disease that is specialised, however, some of the treatments used to manage blood cancers are within specialised services, such as HSCT. NHS England publishes national service specifications for specialised services and monitors the quality-of-service provision and patient outcomes via the NHS England quality dashboards, and in the case of HSCT, by also reviewing the service-level reports published by the British Society of Blood and Marrow Transplantation and Cellular Therapy. The findings of the reviews of these reports are discussed with NHS England regional teams who determine any appropriate action that needs to be taken with the providers within their region.

What steps he is taking to ensure equitable access to specialist blood cancer treatment for patients in rural areas.

Reducing the number of lives lost to cancer is a key aim of the National Cancer Plan, which will be published later this year. The plan will include further details on how we will improve outcomes for cancer patients, including blood cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, ultimately driving up this country’s cancer survival rates. The National Cancer Plan will have patients at its heart, and the Department has been working closely with patient organisations and other cancer partners as part of our engagement to inform the development of the plan. This includes patient and family engagement events with partners such as Macmillan and Maggies, and engagement with blood cancer charities and the NHS Patient and Public Voice Forum.Early diagnosis is a key focus of the National Cancer Plan. It is a priority for the Government to support the National Health Service to diagnose cancer, including blood cancers, as early and quickly as possible, and to treat it faster, to improve outcomes. To tackle the late diagnoses of blood cancers, the NHS is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways. We will get the NHS diagnosing blood cancers earlier and treating them faster, and we will support the NHS to increase capacity to meet the demand for diagnostic services through investment, including for magnetic resonance imaging and computed tomography scanners. Furthermore, the 10-Year Health Plan’s commitment to putting digital health at the heart of the future health service, and integrating that with a single patient record and neighbourhood health services, will mean that cancer patients will get the joined-up care they deserve.The National Cancer Plan will also seek to ensure that high-quality care is available to patients across the country, including patients in rural areas. This will build on the current national cancer audits, which are seeking to promote best practice and aim to reduce inequalities in the access to, or the quality of, treatment. Further details on the steps that will be taken to achieve this will be set out in the plan. Service providers are responsible for making clinical decisions about prioritisation in response to capacity constraints, taking into consideration national guidance, and access and waiting time standards, so that patients are prioritised.Haematopoietic stem cell transplantation (HSCT) is a potential treatment for a range of malignant and non-malignant indications, including myeloma. HSCT is a specialised service and is the commissioning responsibility of integrated care boards.NHS England is the accountable commissioner for HSCT and has published a national service specification that all commissioned HSCT services need to meet. The list of commissioned indications is covered by the NHS England Clinical Commissioning Policy available at the following link:https://www.england.nhs.uk/wp-content/uploads/2022/10/Haematopoietic-Stem-Cell-Transplantation-HSCT-All-Ages.pdfThere are currently no plans to expand the number of specialised centres that deliver HSCT treatments.Blood cancer in and of itself is not a disease that is specialised, however, some of the treatments used to manage blood cancers are within specialised services, such as HSCT. NHS England publishes national service specifications for specialised services and monitors the quality-of-service provision and patient outcomes via the NHS England quality dashboards, and in the case of HSCT, by also reviewing the service-level reports published by the British Society of Blood and Marrow Transplantation and Cellular Therapy. The findings of the reviews of these reports are discussed with NHS England regional teams who determine any appropriate action that needs to be taken with the providers within their region.

What steps he is taking to improve five-year survival rates for patients with acute myeloid leukaemia.

Reducing the number of lives lost to cancer is a key aim of the National Cancer Plan, which will be published later this year. The plan will include further details on how we will improve outcomes for cancer patients, including blood cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, ultimately driving up this country’s cancer survival rates. The National Cancer Plan will have patients at its heart, and the Department has been working closely with patient organisations and other cancer partners as part of our engagement to inform the development of the plan. This includes patient and family engagement events with partners such as Macmillan and Maggies, and engagement with blood cancer charities and the NHS Patient and Public Voice Forum.Early diagnosis is a key focus of the National Cancer Plan. It is a priority for the Government to support the National Health Service to diagnose cancer, including blood cancers, as early and quickly as possible, and to treat it faster, to improve outcomes. To tackle the late diagnoses of blood cancers, the NHS is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways. We will get the NHS diagnosing blood cancers earlier and treating them faster, and we will support the NHS to increase capacity to meet the demand for diagnostic services through investment, including for magnetic resonance imaging and computed tomography scanners. Furthermore, the 10-Year Health Plan’s commitment to putting digital health at the heart of the future health service, and integrating that with a single patient record and neighbourhood health services, will mean that cancer patients will get the joined-up care they deserve.The National Cancer Plan will also seek to ensure that high-quality care is available to patients across the country, including patients in rural areas. This will build on the current national cancer audits, which are seeking to promote best practice and aim to reduce inequalities in the access to, or the quality of, treatment. Further details on the steps that will be taken to achieve this will be set out in the plan. Service providers are responsible for making clinical decisions about prioritisation in response to capacity constraints, taking into consideration national guidance, and access and waiting time standards, so that patients are prioritised.Haematopoietic stem cell transplantation (HSCT) is a potential treatment for a range of malignant and non-malignant indications, including myeloma. HSCT is a specialised service and is the commissioning responsibility of integrated care boards.NHS England is the accountable commissioner for HSCT and has published a national service specification that all commissioned HSCT services need to meet. The list of commissioned indications is covered by the NHS England Clinical Commissioning Policy available at the following link:https://www.england.nhs.uk/wp-content/uploads/2022/10/Haematopoietic-Stem-Cell-Transplantation-HSCT-All-Ages.pdfThere are currently no plans to expand the number of specialised centres that deliver HSCT treatments.Blood cancer in and of itself is not a disease that is specialised, however, some of the treatments used to manage blood cancers are within specialised services, such as HSCT. NHS England publishes national service specifications for specialised services and monitors the quality-of-service provision and patient outcomes via the NHS England quality dashboards, and in the case of HSCT, by also reviewing the service-level reports published by the British Society of Blood and Marrow Transplantation and Cellular Therapy. The findings of the reviews of these reports are discussed with NHS England regional teams who determine any appropriate action that needs to be taken with the providers within their region.

What steps he is taking to monitor progress on access to new NHS-approved drugs for blood cancer patients.

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. NICE has been able to recommend a number of medicines for use in the NHS for the treatment of different types of blood cancer.NHS England funds NICE-recommended cancer medicines from the Cancer Drugs Fund from the point of a positive draft NICE guidance, bringing forward patient access by approximately five months than would otherwise be the case. All drugs on the Cancer Drugs Fund have reached expected uptake levels within three months of a positive NICE recommendation.

What discussions his Department has had with NHS England on incorporating fracture liaison services into the national 10-Year Health Plan.

Fracture Liaison Services are commissioned by integrated care boards, which are well-placed to make decisions according to local need.Our 10-Year Health Plan committed to rolling out Fracture Liaison Services across every part of the country by 2030.Officials continue to work closely with NHS England to explore a range of options to provide better quality and access to these important preventative services.

What steps his Department is taking to ensure equitable access to osteoporosis medication and early diagnosis services across all regions of England.

In the last three years, two new drugs have been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of osteoporosis in post-menopausal women, namely abaloparatide and romosozumab. These medications help to strengthen the bones and prevent bone loss, thereby reducing the risk of fractures. The National Health Service is legally required to make funding available for treatments recommended by NICE.We have invested in 13 new bone density, or DEXA, scanners, which are expected to provide up to 29,000 extra scans per year to ensure people with bone conditions get diagnosed earlier.The National Fracture Liaison Service database is a clinically led national audit of secondary fracture prevention in England and Wales and is commissioned by the Healthcare Quality Improvement Partnership and delivered by the Royal College of Physicians. It collects and publishes data on individual Fracture Liaison Services and uses internationally recognised standards as the key performance indicators that these services are measured against. The data is publicly available.

What his planned timetable is for the national roll-out of Fracture Liaison Services.

Fracture Liaison Services are commissioned by integrated care boards, which are well-placed to make decisions according to local need.Our 10-Year Health Plan committed to rolling out Fracture Liaison Services across every part of the country by 2030.Officials continue to work closely with NHS England to explore a range of options to provide better quality and access to these important preventative services.